Biogen Ranked #1 Biotechnology Company by Dow Jones Sustainability World Index for an Industry Record 5th Time; Recognition ...
November 16 2020 - 7:30AM
Biogen Ranked #1 Biotechnology Company by Dow Jones Sustainability
World Index for an Industry Record 5th Time; Recognition Reflects
Longstanding ESG Leadership
Biogen Inc. (Nasdaq: BIIB) today announced that it has been
ranked the number one biotechnology company on the Dow Jones
Sustainability World Index (DJSI World Index) for the fifth time,
more than any other biotechnology company. The DJSI World Index
recognizes the top 10 percent of companies in the S&P Global
Broad Market Index for performance on environmental, social and
governance (ESG) issues, which S&P Global considers key to
generating long-term stakeholder value.
Of the 318 companies named to DJSI World Index,
Biogen led the biotechnology industry with the top scores in areas
such as strategies to improve access to medicine and cost burden,
innovation management, talent attraction, climate performance and
reporting. In 2013 Biogen was the first U.S.-based biotech company
to appear on DJSI World Index, and 2020 marks the eighth
consecutive year that Biogen was listed among top corporate
performers.
“At Biogen, we believe that responsible corporate
leadership is a defining part of our culture and our ongoing
business success. We are proud to top the DJSI World Index for the
fifth time, an achievement that reflects Biogen’s longstanding
commitment to making advances in climate, health, equity and other
urgent issues of our time while pioneering neuroscience,” said
Michel Vounatsos, Chief Executive Officer of Biogen.
The DJSI World Index ranking results from Biogen’s
outstanding performance on multiple dimensions of corporate
responsibility, including an ongoing focus on health equity and
access; ethical marketing practices; and human capital development
with a focus on diversity, equity and inclusion. It also reflects
Biogen’s emphasis on transparency and expanded public reporting on
emerging risks, employee benefits and philanthropic contributions,
among other issues.
“We congratulate Biogen for being included in the
DJSI World Index. A DJSI distinction is a reflection of being a
sustainability leader in your industry,” said Manjit Jus, Global
Head of ESG Research and Data, S&P Global. “With a record
number of companies participating in the 2020 Corporate
Sustainability Assessment and more stringent rules for inclusion
this year, this sets your company apart and rewards your continued
commitment to people and planet.”
To bolster its ESG commitments, Biogen recently
launched Healthy Climate, Healthy LivesTM, a 20-year initiative to
eliminate fossil fuels across its operations and collaborate with
renowned institutions to advance human health. The program includes
research into the potential link between dementia and air
pollution.
Details on Biogen’s ESG commitments can be found in
its 2019 Year In Review, which is based on internationally
recognized Global Reporting Initiative (GRI) G4 Guidelines.
About BiogenAt Biogen, our mission
is clear: we are pioneers in neuroscience. Biogen discovers,
develops and delivers worldwide innovative therapies for people
living with serious neurological and neurodegenerative diseases as
well as related therapeutic adjacencies. One of the world’s first
global biotechnology companies, Biogen was founded in 1978 by
Charles Weissmann, Heinz Schaller, Kenneth Murray and Nobel Prize
winners Walter Gilbert and Phillip Sharp. Today Biogen has the
leading portfolio of medicines to treat multiple sclerosis, has
introduced the first approved treatment for spinal muscular
atrophy, commercializes biosimilars of advanced biologics and is
focused on advancing research programs in multiple sclerosis and
neuroimmunology, Alzheimer’s disease and dementia, neuromuscular
disorders, movement disorders, ophthalmology, immunology,
neurocognitive disorders, acute neurology and pain.
We routinely post information that may be important
to investors on our website at www.biogen.com. To learn more,
please visit www.biogen.com and follow us on social media –
Twitter, LinkedIn, Facebook, YouTube.
Biogen Safe HarborThis news
release contains forward-looking statements, including statements
made pursuant to the safe harbor provisions of the Private
Securities Litigation Reform Act of 1995, about our strategy and
plans; and our ability to achieve our ESG goals, commitments and
targets. These statements may be identified by words such as “aim,”
“anticipate,” “believe,” “could,” “estimate,” “expect,” “forecast,”
“goal,” “intend,” “may,” “plan,” “possible,” “potential,” “will,”
“would” and other words and terms of similar meaning. You should
not place undue reliance on these statements.
These statements involve risks and uncertainties
that could cause actual results to differ materially from those
reflected in such statements, including without limitation the
risks of unexpected hurdles, costs or delays; uncertainty of
success in the execution of our strategy and plans; the direct and
indirect impact of the ongoing COVID-19 pandemic on our business,
results of operations and financial condition; and the risks and
uncertainties that are described in the Risk Factors section of our
most recent annual or quarterly report and in other reports we have
filed with the U.S. Securities and Exchange Commission. The
foregoing sets forth many, but not all, of the factors that could
cause actual results to differ from our expectations in any
forward-looking statement. Investors should consider this
cautionary statement, as well as the risk factors identified in our
most recent annual or quarterly report and in other reports we have
filed with the U.S. Securities and Exchange Commission. These
statements are based on our current beliefs and expectations and
speak only as of the date of this news release. We do not undertake
any obligation to publicly update any forward-looking statements,
whether as a result of new information, future developments or
otherwise.
MEDIA CONTACT :David Caouette+ 1 617 679
4945public.affairs@biogen.com |
INVESTOR CONTACT:Joe Mara+1 781 464 2442IR@biogen.com |
Biogen (TG:IDP)
Historical Stock Chart
From Jun 2024 to Jul 2024
Biogen (TG:IDP)
Historical Stock Chart
From Jul 2023 to Jul 2024